Appili Therapeutics Inc. (TSX:APLI)
Canada · Delayed Price · Currency is CAD | Market Cap | 2.57M |
| Revenue (ttm) | 199.69K |
| Net Income (ttm) | -2.53M |
| Shares Out | 128.37M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,000 |
| Average Volume | 55,671 |
| Open | 0.0200 |
| Previous Close | 0.0200 |
| Day's Range | 0.0200 - 0.0200 |
| 52-Week Range | 0.0100 - 0.0450 |
| Beta | 0.14 |
| RSI | 45.38 |
| Earnings Date | Feb 13, 2026 |
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company ... [Read more]
Financial Performance
In 2024, Appili Therapeutics's revenue was 100,443, a decrease of -87.86% compared to the previous year's 827,407. Losses were -2.62 million, -30.58% less than in 2023.
Financial StatementsNews
Appili Therapeutics Inc. GAAP EPS of -$0.01
Appili Therapeutics Q2 Sales Increase
(RTTNews) - Appili Therapeutics (APLIF) revealed Loss for second quarter of -C$0.99 million
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships...
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for i...
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat Appili Non-Clinical Director to join NATO a...
Appili Therapeutics GAAP EPS of -$0.01
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Peer-reviewed publication highlights ATI-1701's robust protection against aerosolized Francisella tularensis exposure in multiple animal models
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia...
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: A...
Aditxt to terminate arrangement agreement with Appili Therapeutics
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: A...
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
A review of recent findings suggests that Appili's biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks A review of recent findings suggests that Appili's biodefense vaccine...
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NE...
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private transaction...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Inv...
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFA...
Appili Therapeutics reports Q2 results
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal mo...
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an im...
Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: ...
Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an im...